Matches in SemOpenAlex for { <https://semopenalex.org/work/W2788507110> ?p ?o ?g. }
- W2788507110 endingPage "346" @default.
- W2788507110 startingPage "335" @default.
- W2788507110 abstract "Background Improved understanding is needed of risk factors and markers of disease progression in preclinical Alzheimer's disease. We assessed associations between brain β-amyloidosis and various cognitive and neuroimaging parameters with progression of cognitive decline in individuals with preclinical Alzheimer's disease. Methods The INSIGHT-preAD is an ongoing single-centre observational study at the Salpêtrière Hospital, Paris, France. Eligible participants were age 70–85 years with subjective memory complaints but unimpaired cognition and memory (Mini-Mental State Examination [MMSE] score ≥27, Clinical Dementia Rating score 0, and Free and Cued Selective Reminding Test [FCSRT] total recall score ≥41). We stratified participants by brain amyloid β deposition on 18F-florbetapir PET (positive or negative) at baseline. All patients underwent baseline assessments of demographic, cognitive, and psychobehavioural, characteristics, APOE ε4 allele carrier status, brain structure and function on MRI, brain glucose-metabolism on 18F-fluorodeoxyglucose (18F-FDG) PET, and event-related potentials on electroencephalograms (EEGs). Actigraphy and CSF investigations were optional. Participants were followed up with clinical, cognitive, and psychobehavioural assessments every 6 months, neuropsychological assessments, EEG, and actigraphy every 12 months, and MRI, and 18F-FDG and 18F-florbetapir PET every 24 months. We assessed associations of amyloid β deposition status with test outcomes at baseline and 24 months, and with clinical status at 30 months. Progression to prodromal Alzheimer's disease was defined as an amnestic syndrome of the hippocampal type. Findings From May 25, 2013, to Jan 20, 2015, we enrolled 318 participants with a mean age of 76·0 years (SD 3·5). The mean baseline MMSE score was 28·67 (SD 0·96), and the mean level of education was high (score >6 [SD 2] on a scale of 1–8, where 1=infant school and 8=higher education). 88 (28%) of 318 participants showed amyloid β deposition and the remainder did not. The amyloid β subgroups did not differ for any psychobehavioural, cognitive, actigraphy, and structural and functional neuroimaging results after adjustment for age, sex, and level of education More participants positive for amyloid β deposition had the APOE ε4 allele (33 [38%] vs 29 [13%], p<0·0001). Amyloid β1–42 concentration in CSF significantly correlated with mean 18F-florbetapir uptake at baseline (r=–0·62, p<0·0001) and the ratio of amyloid β1–42 to amyloid β1–40 (r=–0·61, p<0·0001), and identified amyloid β deposition status with high accuracy (mean area under the curve values 0·89, 95% CI 0·80–0·98 and 0·84, 0·72–0·96, respectively). No difference was seen in MMSE (28·3 [SD 2·0] vs 28·9 [1·2], p=0·16) and Clinical Dementia Rating scores (0·06 [0·2] vs 0·05 [0·3]; p=0·79) at 30 months (n=274) between participants positive or negative for amyloid β. Four participants (all positive for amyloid β deposition at baseline) progressed to prodromal Alzheimer's disease. They were older than other participants positive for amyloid β deposition at baseline (mean 80·2 years [SD 4·1] vs 76·8 years [SD 3·4]) and had greater 18F-florbetapir uptake at baseline (mean standard uptake value ratio 1·46 [SD 0·16] vs 1·02 [SD 0·20]), and more were carriers of the APOE ε4 allele (three [75%] of four vs 33 [39%] of 83). They also had mild executive dysfunction at baseline (mean FCSRT free recall score 21·25 [SD 2·75] vs 29·08 [5·44] and Frontal Assessment Battery total score 13·25 [1·50] vs 16·05 [1·68]). Interpretation Brain β-amyloidosis alone did not predict progression to prodromal Alzheimer's disease within 30 months. Longer follow-up is needed to establish whether this finding remains consistent. Funding Institut Hospitalo-Universitaire and Institut du Cerveau et de la Moelle Epinière (IHU-A-ICM), Ministry of Research, Fondation Plan Alzheimer, Pfizer, and Avid. Improved understanding is needed of risk factors and markers of disease progression in preclinical Alzheimer's disease. We assessed associations between brain β-amyloidosis and various cognitive and neuroimaging parameters with progression of cognitive decline in individuals with preclinical Alzheimer's disease. The INSIGHT-preAD is an ongoing single-centre observational study at the Salpêtrière Hospital, Paris, France. Eligible participants were age 70–85 years with subjective memory complaints but unimpaired cognition and memory (Mini-Mental State Examination [MMSE] score ≥27, Clinical Dementia Rating score 0, and Free and Cued Selective Reminding Test [FCSRT] total recall score ≥41). We stratified participants by brain amyloid β deposition on 18F-florbetapir PET (positive or negative) at baseline. All patients underwent baseline assessments of demographic, cognitive, and psychobehavioural, characteristics, APOE ε4 allele carrier status, brain structure and function on MRI, brain glucose-metabolism on 18F-fluorodeoxyglucose (18F-FDG) PET, and event-related potentials on electroencephalograms (EEGs). Actigraphy and CSF investigations were optional. Participants were followed up with clinical, cognitive, and psychobehavioural assessments every 6 months, neuropsychological assessments, EEG, and actigraphy every 12 months, and MRI, and 18F-FDG and 18F-florbetapir PET every 24 months. We assessed associations of amyloid β deposition status with test outcomes at baseline and 24 months, and with clinical status at 30 months. Progression to prodromal Alzheimer's disease was defined as an amnestic syndrome of the hippocampal type. From May 25, 2013, to Jan 20, 2015, we enrolled 318 participants with a mean age of 76·0 years (SD 3·5). The mean baseline MMSE score was 28·67 (SD 0·96), and the mean level of education was high (score >6 [SD 2] on a scale of 1–8, where 1=infant school and 8=higher education). 88 (28%) of 318 participants showed amyloid β deposition and the remainder did not. The amyloid β subgroups did not differ for any psychobehavioural, cognitive, actigraphy, and structural and functional neuroimaging results after adjustment for age, sex, and level of education More participants positive for amyloid β deposition had the APOE ε4 allele (33 [38%] vs 29 [13%], p<0·0001). Amyloid β1–42 concentration in CSF significantly correlated with mean 18F-florbetapir uptake at baseline (r=–0·62, p<0·0001) and the ratio of amyloid β1–42 to amyloid β1–40 (r=–0·61, p<0·0001), and identified amyloid β deposition status with high accuracy (mean area under the curve values 0·89, 95% CI 0·80–0·98 and 0·84, 0·72–0·96, respectively). No difference was seen in MMSE (28·3 [SD 2·0] vs 28·9 [1·2], p=0·16) and Clinical Dementia Rating scores (0·06 [0·2] vs 0·05 [0·3]; p=0·79) at 30 months (n=274) between participants positive or negative for amyloid β. Four participants (all positive for amyloid β deposition at baseline) progressed to prodromal Alzheimer's disease. They were older than other participants positive for amyloid β deposition at baseline (mean 80·2 years [SD 4·1] vs 76·8 years [SD 3·4]) and had greater 18F-florbetapir uptake at baseline (mean standard uptake value ratio 1·46 [SD 0·16] vs 1·02 [SD 0·20]), and more were carriers of the APOE ε4 allele (three [75%] of four vs 33 [39%] of 83). They also had mild executive dysfunction at baseline (mean FCSRT free recall score 21·25 [SD 2·75] vs 29·08 [5·44] and Frontal Assessment Battery total score 13·25 [1·50] vs 16·05 [1·68]). Brain β-amyloidosis alone did not predict progression to prodromal Alzheimer's disease within 30 months. Longer follow-up is needed to establish whether this finding remains consistent." @default.
- W2788507110 created "2018-03-06" @default.
- W2788507110 creator A5002348728 @default.
- W2788507110 creator A5003323445 @default.
- W2788507110 creator A5005778444 @default.
- W2788507110 creator A5009712890 @default.
- W2788507110 creator A5016497611 @default.
- W2788507110 creator A5017275450 @default.
- W2788507110 creator A5020944505 @default.
- W2788507110 creator A5021647808 @default.
- W2788507110 creator A5024848742 @default.
- W2788507110 creator A5025288625 @default.
- W2788507110 creator A5029597969 @default.
- W2788507110 creator A5030862734 @default.
- W2788507110 creator A5031924662 @default.
- W2788507110 creator A5032131314 @default.
- W2788507110 creator A5034703590 @default.
- W2788507110 creator A5035330581 @default.
- W2788507110 creator A5035338217 @default.
- W2788507110 creator A5035612340 @default.
- W2788507110 creator A5035699131 @default.
- W2788507110 creator A5037109052 @default.
- W2788507110 creator A5037665944 @default.
- W2788507110 creator A5040247607 @default.
- W2788507110 creator A5041147756 @default.
- W2788507110 creator A5043702011 @default.
- W2788507110 creator A5045684352 @default.
- W2788507110 creator A5045763915 @default.
- W2788507110 creator A5046900294 @default.
- W2788507110 creator A5050623251 @default.
- W2788507110 creator A5052197126 @default.
- W2788507110 creator A5052675388 @default.
- W2788507110 creator A5054045089 @default.
- W2788507110 creator A5054788080 @default.
- W2788507110 creator A5057798463 @default.
- W2788507110 creator A5061740933 @default.
- W2788507110 creator A5062628381 @default.
- W2788507110 creator A5063449109 @default.
- W2788507110 creator A5067992372 @default.
- W2788507110 creator A5068377025 @default.
- W2788507110 creator A5068972900 @default.
- W2788507110 creator A5069204609 @default.
- W2788507110 creator A5069514442 @default.
- W2788507110 creator A5071593805 @default.
- W2788507110 creator A5074168134 @default.
- W2788507110 creator A5075804608 @default.
- W2788507110 creator A5078737983 @default.
- W2788507110 creator A5078876988 @default.
- W2788507110 creator A5079125675 @default.
- W2788507110 creator A5079628658 @default.
- W2788507110 creator A5079882077 @default.
- W2788507110 creator A5080254367 @default.
- W2788507110 creator A5083260688 @default.
- W2788507110 creator A5084534846 @default.
- W2788507110 creator A5089797917 @default.
- W2788507110 creator A5089882765 @default.
- W2788507110 creator A5090536391 @default.
- W2788507110 creator A5090558659 @default.
- W2788507110 creator A5090830124 @default.
- W2788507110 creator A5090971117 @default.
- W2788507110 creator A5091618250 @default.
- W2788507110 creator A5091645945 @default.
- W2788507110 date "2018-04-01" @default.
- W2788507110 modified "2023-10-17" @default.
- W2788507110 title "Cognitive and neuroimaging features and brain β-amyloidosis in individuals at risk of Alzheimer's disease (INSIGHT-preAD): a longitudinal observational study" @default.
- W2788507110 cites W1519378085 @default.
- W2788507110 cites W1563091671 @default.
- W2788507110 cites W1836749191 @default.
- W2788507110 cites W1847168837 @default.
- W2788507110 cites W1951284594 @default.
- W2788507110 cites W1972025839 @default.
- W2788507110 cites W1980827933 @default.
- W2788507110 cites W1983182638 @default.
- W2788507110 cites W1984123948 @default.
- W2788507110 cites W1984624356 @default.
- W2788507110 cites W1991714215 @default.
- W2788507110 cites W1991952617 @default.
- W2788507110 cites W1995779519 @default.
- W2788507110 cites W2010695389 @default.
- W2788507110 cites W2017122588 @default.
- W2788507110 cites W2022304840 @default.
- W2788507110 cites W2025262281 @default.
- W2788507110 cites W2044429455 @default.
- W2788507110 cites W2048505725 @default.
- W2788507110 cites W2051489981 @default.
- W2788507110 cites W2051737015 @default.
- W2788507110 cites W2071686284 @default.
- W2788507110 cites W2087011519 @default.
- W2788507110 cites W2096063777 @default.
- W2788507110 cites W2098684027 @default.
- W2788507110 cites W2106931873 @default.
- W2788507110 cites W2111963393 @default.
- W2788507110 cites W2112519660 @default.
- W2788507110 cites W2113176889 @default.
- W2788507110 cites W2115017507 @default.
- W2788507110 cites W2116709840 @default.
- W2788507110 cites W2129497119 @default.
- W2788507110 cites W2129771097 @default.